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Study  of ankle brachial index in systemic hypertension.  
 
ABSTRACT 
 
Background 
Asymptomatic peripheral artery disease is common in patients with systemic 
hypertension. Ankle brachial index is an easy method to detect asymptomatic 
peripheral artery disease. ABI of ≤ 0.9 indicates peripheral artery disease. Presence 
of peripheral artery disease indicates the presence of atherosclerosis and predicts   
high cardiovascular risk. 
Aim: To study the effect of systemic  hypertension on ankle brachial index and to 
assess the effect of age, sex, body mass index and duration of hypertension on 
ankle brachial index. 
Methods: After excluding the patients with exclusion criteria 198 hypertensive 
patients who visited   the department of medicine, Kilpauk medical college hospital 
were studied. Patient details were recorded as per the proforma which included  
age, sex, BMI, duration of hypertension, ankle brachial index. Data was 
maintained in master chart and analysed. 
Results: Prevalence of asymptomatic PAD was 47% in this study. ABI was ≤0.9 in 
46.8% of males in this study. ABI was ≤0.9 in 47.8% of females in this study. 
There was inverse correlation between age and ABI. There was inverse correlation 
between duration of hypertension and ABI. There was inverse correlation between 
pulse pressure and ABI. There was inverse correlation between ABI and BMI. 
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INTRODUCTION 
Hypertension is considered to be one of the leading causes of 
morbidity globally. Approximately 7.6 million deaths (13–15% of the 
total) and 92 million disability-adjusted life years globally are due to 
hypertension. Hypertension increases the risk of cardiovascular disease, 
renal failure, and peripheral arterial disease. It adds to the total burden of 
cardio vascular risk factors if other risk factors are also present.  
Blood vessels are main structures contributing to the development 
of hypertension. At the same time they are the target organs for long 
standing elevated blood pressure. Hypertensive patients with peripheral 
arterial disease are found to have increased future cardiovascular events. 
Hypertension holds the responsibility for most of the stroke deaths 
and coronary artery disease deaths in India.  Hence early diagnosis and 
treatment of complications is very important so as to reduce the morbidity 
and mortality in the high risk population. 
Ankle brachial index (ABI) is a simple and non invasive tool to 
assess the peripheral artery disease. It indicates the presence of 
atherosclerosis in the peripheral blood vessel. It is a powerful indicator of 
generalized atherosclerotic disease including coronary arteries.  
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Diagnosing PAD is  clinically important for these  reasons: 
The first is to identify patients with elevated risk of myocardial 
infarction or stroke irrespective of symptoms of   PAD 
The second is to treat the symptoms of   PAD to reduce the 
functional disability and limb loss.  
Peripheral artery disease usually presents with intermittent 
claudication. Peripheral artery disease becomes  a marker for systemic 
vascular disease as atherosclerosis is the basic pathology in other vessels 
also. Thus it helps in  predicting  ongoing atherosclerosis in systemic 
vessels  involving coronary, cerebral, and renal vessels  which may lead 
to an elevated risk of events like myocardial infarction (MI), stroke, and 
death.  
Ankle Brachial Index(ABI) helps in making reliable diagnosis of 
the peripheral artery disease. Ankle brachial index is a ratio having  
systolic blood pressure in the ankle as numerator and  systolic blood 
pressure in the arm as denominator. Measurement of ABI is simple and 
requires a blood pressure apparatus and a hand held Doppler probe. An 
ABI of less <=0.9 is considered  as low ABI .It indicates presence  of  
peripheral artery disease. 
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Patients with peripheral artery disease (PAD) of the lower limbs 
are at higher risk of premature death related to cardiovascular events 
irrespective of presence of symptoms. Hence early detection of peripheral 
artery disease gains importance as these patients will benefit from 
cardiovascular risk factor modification. 
 
Hypertension is a known risk factor for peripheral arterial 
disease.(PAD)  along with diabetes and  smoking.   The present study 
aims at prevalence of this condition in hypertensive patients without co 
morbidities. The measurement of ABI is easy to take. It is non invasive 
and   safe , thus patient friendly . Hence it can be used to screen for lower 
limb ischemia in hypertensive patients. 
 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE  
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SYSTEMIC HYPERTENSION 
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Systemic hypertension 
Hypertension is a non communicable disease. It is prevalent in both 
developing and developed countries. It is a chronic condition. It is of 
great   concern as it is a major risk factor for coronary heart disease, 
stroke and other vascular complications.    
 Definitions 
According to the Seventh Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), 
the following are the definitions  which can be used in the blood pressure 
evaluation: 
   
▪     Systolic  BP <120 and diastolic  BP < 80 mm Hg is considered to be 
normal blood pressure. 
   
▪    120 to 139 mm Hg systolic or  80 to 89 mm Hg diastolic is 
considered as prehypertension 
   
▪    Hypertension:  
Stage 1—140 to 159 mm Hg systolic or 90 to 99 mm Hg diastolic 
 Stage 2— 160 mm Hg systolic or > 100 mm Hg diastolic  
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Epidemiologic studies have shown that there is a gradual but 
definite  increase in cardiovascular risk with increasing  blood pressure 
above even “normal” values of 110/75 mm Hg[1][4][5][6][7]. So the concept 
of prehypertension has emerged. These patients are at risk to develop 
overt hypertension, with those in the 130/80 to 139/89 mm Hg range 
being twice as likely to become hypertensive[1]. Patients who have 
isolated systolic hypertension will have systolic hypertension yet 
managed to have diastolic pressures lower than 90 mm Hg. 
 
Hypertension due to an identifiable cause is known as secondary 
hypertension. Idiopathic or primary hypertension is referred to as 
essential hypertension. Approximately 25% of essential hypertension 
patients have low-renin essential hypertension.[8]  It is found that such 
patients are  more salt sensitive[9]. They are at relatively low risk for 
myocardial infarction[10]  and less likely to respond to weight reduction[11].  
They may be African American or elderly[12] ,and they  may show a  
pronounced response to drugs like  diuretics and calcium-channel blocker 
agents[13]. 
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It is very important to detect secondary causes of hypertension 
when there is atypical presentation. Secondary hypertension should be 
considered when hypertension presents in a younger age or its not 
responding to usual antihypertensive medications. Different etiologies 
have to be considered and different tools for diagnosis should be 
judiciously employed as and when needed to arrive at the cause based on 
clinical suspicion. 
The common causes of secondary hypertension are  
1. renal disease 
2. pheochromocytoma;  
3. Cushing’s syndrome 
4. primary hyperaldosteronism 
5. hypothyroidism  
6. hyperthyroidism 
7. oral contraceptives  
8. hyperparathyroidism 
9. coarctation of the aorta  
10. obstructive  sleep apnea syndrome . 
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 If 24-hour average blood pressure is greater than 135/85 mm Hg 
or a daytime average of 140/90 mm Hg it is known as ambulatory 
hypertension. There are devices which measure the blood pressure 
throughout the day at definite predetermined intervals. These devices help 
in detecting ambulatory hypertension. These can be used to evaluate 
white coat hypertension. 
                        
Resistant hypertension is defined as a diastolic blood pressure 
greater than 95 to 100 mm Hg despite the usage of three or more 
antihypertensives. Malignant hypertension is a serious condition. It will 
have  marked  hypertension with  retinal exudates,  retinal hemorrhage  or  
papilledema. It is associated with end organ damage. 
 
 
 
 
 
 
11 
 
 SYSTEMIC HYPERTENSION AND CARDIOVASCULAR RISK 
Systemic hypertension is a major risk for  atherosclerosis[14]. There 
is clear evidence from  epidemiologic studies that the cardiovascular risk 
increases gradually with  the blood pressure  greater than  even “normal” 
values of 110/75 mm Hg1][4][5][6][7]. It holds good more for individuals 
aged 40 to 70 years, with  each  increase of 20 mm Hg in systolic blood 
pressure or 10 mm Hg in diastolic blood pressure .  
The risk of cardiovascular disease (CVD) increases by two fold 
with each increase of 20 mm Hg in systolic blood pressure or 10 mm Hg 
in diastolic blood pressure in individuals aged 50-70 years. Blood 
pressure lowering has been shown to improve the outcome.[16][17][18] . It is 
proved in clinical trials that stroke incidence is reduced by 35% to 40% 
with the help of anti hypertensive therapy.  
Antihypertensive therapy helps reducing  myocardial infarction 
incidence  by 20% to 25% . Treating hypertension is shown to reduce 
heart failure incidence by more than 50%[19]. There is evidence that in 
patients with stage 1 hypertension with other cardio vascular disease risk 
factors , reducing systolic blood pressure 12 mm Hg for 10 years prevents  
one death for every 11 patients treated. If CVD or PAD or target end-
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organ damage is present in these patients, to prevent one death  9 patients 
should be treated [20]. 
In patients with diabetes and chronic renal failure   lowering the 
blood pressure  is effective in prehypertensive stage[1]. Pulse pressure is 
also associated with increased risk[16][17][18].  As age advances arterial 
compliance decreases. This results in decrease in diastolic pressure and 
increase in   systolic pressure. This is the reason why increased systolic 
and pulse pressure are  more predictive of risk in older individuals[16] 
.Even with short-term therapy more beneficial effects of antihypertensive 
therapy can be witnessed in these subgroup of patients.[21][22]  Systolic 
hypertension is  the best predictor of cardiovascular risk in hypertensive 
patients aged 50 to 60 years, whereas it is the diastolic pressure in 
patients younger than 50 years[16]. 
Control of diastolic blood pressures above 105 mm Hg  is 
associated with reduced  incidence of cardiovascular events (55% vs. 
17% at 5 years)[23]. This  benefit may not be as marked in patients with  
mild diastolic hypertension of 90 to 100 mm Hg. Hebert et al,[24]showed 
that treatment of mild diastolic hypertension for 4 to 5 years prevents a 
coronary event in 0.7% of  subjects  and a cerebro vascular event in 
1.3%.This was a short duration study. In this cardiovascular death was 
lowered by only 0.8%.  The benefit of treatment is better with long term 
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antihypertensive therapy. In fact, in   Framingham Heart Study, the 
cardiovascular death risk  for treated patients versus untreated patients 
was 0.4% over 10 years.[25] 
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MECHANISMS OF  SYSTEMIC HYPERTENSION 
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 It is important to know the mechanisms involved in regulation of  
normal blood pressure and elevated blood pressure  to understand 
pathogenesis and treatment options. Both cardiac output and peripheral 
resistance are the two major factors involved in maintaining the arterial 
blood pressure .Stroke volume and heart rate are involved in determining 
the cardiac output. Contractility of the cardiac muscle and vascular 
compartment size contribute to the stroke volume. 
                                                                                     Vascular structure 
                                                 Peripheral resistance 
                                                                                       Vascular function 
      Arterial pressure 
                                                                                              Stroke volume 
                                               Cardiac output 
 
                                                                                                   Heart rate  
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Intravascular Volume 
Vascular volume seems to be the major determinant of arterial 
blood pressure in the long run. Extracellular fluid volume is mainly 
dependant on sodium ion which is a major extracellular cation. When 
sodium chloride intake is more than the capacity of the kidneys to handle 
sodium, there will be initial expansion of intracellular volume and 
increase in cardiac output.  Auto regulation of blood flow is seen in many 
vascular beds. This includes  kidney and brain.  
 
When there is elevated blood pressure vascular resistance has to 
increase to maintain constant flow of blood.  Because  blood flow 
depends on pressure and resistance. 
                                            Pressure across the vessel 
Blood flow   =                        
                                         resistance offered by the vessel 
When there is volume expansion initial response consists of 
elevated blood pressure due to increased cardiac output. But later 
peripheral resistance increases  
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gradually over time so that cardiac output comes back to normal. The 
effect of sodium on blood pressure is basically due to the provision of 
sodium with chloride,  Nonchloride sodium salts   have little or no role in 
causing elevated  blood pressure. 
 
When  arterial blood pressure increases due to increased sodium 
chloride intake, urinary sodium excretion also tends to increase.  Sodium 
balance is maintained by an increase in arterial blood pressure. Minute 
increases in the glomerular filtration rate, reduced absorbing capacity of 
the renal tubule to absorb sodium, and hormonal factors such as atrial 
natriuretic factor may be involved in causing pressure natriuresis. Greater 
increases in blood pressure are needed to maintain sodium balance. 
 
There can be other mechanisms involved in this sodium chloride 
dependant hypertension. Kidneys may fail to excrete sodium because of 
intrinsic kidney disease, increased formation of mineralocorticoid 
hormone which retains salt by tubular re absorption. Increased neural 
activity to the kidney also increases reabsorption of sodium by the 
kidneys. In all these situations, a higher arterial blood pressure is required 
18 
 
to maintain sodium balance. There are certain disorders where salt 
wasting will be seen. It is found that such disorders are associated with 
low arterial blood pressure. 
 
Hypertension seen in the  End Stage Renal Disease(ESRD) is  
volume-dependent hypertension. In ~80% of ESRD patients, it is found 
that dialysis controls vascular volume and hypertension. In the rest 20%, 
it is found that rennin angiotensin system is overactive and contribute to 
hypertension, such patients may benefit from pharmacotherapy.  
 
Autonomic Nervous System 
The autonomic nervous system also plays an important role in 
regulating arterial blood pressure. It is mainly involved in regulating 
cardiovascular homeostasis. It regulates cardiovascular homeostasis with 
the help of volume, pressure,  and chemoreceptor signals.  
Adrenergic reflexes are known to modulate blood pressure over the 
short term. Adrenergic function, in concert with volume-related factors 
and hormonal factors, cause increased blood pressure over long term. The 
three major  endogeneous catecholamines are nor epinephrine, 
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epinephrine, and dopamine. All the three play important roles in tonic and 
phasic cardiovascular regulation in the human body. 
 
Guanosine nucleotide-binding regulatory proteins (G proteins) and  
intracellular  second messengers are found to be the mediators of the 
activity of  adrenergic receptors.. The receptor sites are  specific both for 
the transmitter substance and function . Norepinephrine and epinephrine 
are agonists for adrenergic receptor subtypes with varying affinities.  
 
Adrenergic receptors have been divided into two principal types: α  
and β. These types have been differentiated into α1, α 2, β1, and β2 
receptors. α1 receptors are present on postsynaptic cells in smooth 
muscle. These receptors are known to cause vasoconstriction. α2 
Receptors are present on presynaptic membranes of postganglionic nerve 
terminals which are known to synthesize norepinephrine.  
 
When activated by catecholamines, α2receptors  act as negative 
feedback controllers. They inhibit the release of norepinephrine. α1-
adrenergic receptors enhances renal tubular sodium re absorption 
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.Activation of β 1 receptors in myocardium stimulates the rate and 
strength of cardiac contraction. It increases the cardiac output. β1 
Receptor activation also results in  renin release from the kidney. 
Circulating catecholamine concentrations may affect the number of 
adrenoreceptors in various tissues.  
 
Several reflexes are found to be involved in the regulation of  the 
blood pressure on a minute-to-minute basis. Arterial baroreflex is 
mediated by stretch-sensitive sensory nerve endings. These receptors are 
located in the carotid sinuses and the aortic arch. The firing rate of these  
baroreceptors are found to be increased with increasing arterial blood 
pressure.  The net effect is a decrease in sympathetic outflow. This results 
in reduction in heart rate s well as arterial pressure. 
 
Acute fluctuations of blood pressure occurs during postural 
changes,  physiologic or behavioral stress, and blood volume changes. In 
such acute situations baroreceptors play a vital role in BP regulation. 
However, the baroreflex activity declines overtime. It adapts to sustained 
increases in arterial blood pressure so that the baroreceptors are reset to 
higher blood pressures. Patients with autonomic neuropathy and altered 
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baroreflex function are found to experience   labile blood pressures. They 
will have fluctuations in arterial blood pressure with the difficult-to-
control episodic pressure spikes associated with tachycardia. 
 
Increased sympathetic outflow is associated with hypertension both 
in normal as well as obese individuals. It is found that sympathetic 
outflow is more in hypertensives than in normotensives. This based on 
the recordings of postganglionic muscle nerve activity. Sympathetic 
outflow is more  in obesity-related hypertension as well as  in obstructive 
sleep apnea.  
 
Baroreceptor activation via electrical stimulation of carotid sinus 
has been shown to reduce blood pressure in patients with "resistant" 
hypertension. Drugs blocking the sympathetic nervous system are potent 
antihypertensives. This indicates that the sympathetic nervous system 
plays a permissive role in the maintenance of increased arterial blood 
pressure. Pheochromocytoma is an example of hypertension related to 
increased catecholamine production 
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 Renin-Angiotensin-Aldosterone system 
Renin is a substance secreted by juxtaglomerular cells in the 
kidney in response to the low blood volume. Renin is an aspartyl protease 
that is synthesized as an enzymatically inactive precursor, prorenin. 
Prorenin may be secreted directly into the circulation or it may be 
activated within secretory cells and released as active form of  renin. 
Although human plasma contains two to five times more prorenin than 
renin, there is no evidence that prorenin contributes to the physiologic 
activity of this system. It converts angiotensinogen secreted by liver into 
angiotensin I. Angiotensin I is converted into angiotensin II in the lungs 
by angiotensin converting enzyme. 
 
Angiotensin II is a potent constrictor of blood vessels. So it 
increases blood pressure. It also stimulates adrenal cortex to secrete 
aldosterone. This increases absoption of sodium and water in kidneys. 
This  results in volume expansion and hence, increase in arterial blood 
pressure; 
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There are three primary stimuli for renin secretion:  
1. Decreased NaCl transport in the distal portion of the thick 
ascending limb of the loop of Henle that abuts the corresponding 
afferent arteriole (macula densa), 
2. Decreased pressure or stretch within the renal afferent arteriole 
(baroreceptor mechanism) 
3. Sympathetic nervous system stimulation of renin-secreting cells.  
 
Conversely, NaCl transport in the thick ascending limb of loop of 
Henle inhibits rennin secretion. This effect is mainly  by increased stretch 
within the renal afferent arteriole and by α1 receptor blockade. In 
addition, angiotensin II directly inhibits renin secretion due to angiotensin 
II type 1 receptors on juxtaglomerular cells. It is found that  renin 
secretion increases in response to pharmacologic blockade of either ACE 
or angiotensin II receptors. 
 
Once released into the circulation, active renin cleaves a substrate, 
angiotensinogen, to form an inactive decapeptide, angiotensin I. A 
converting enzyme, located primarily but not exclusively in the 
pulmonary circulation, converts angiotensin I to the  angiotensinII which 
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is an octapeptide. The same converting enzyme cleaves a number of other 
peptides also. This includes vasodilator substance  bradykinin which is 
inactivated.  
 
Angiotensin II  primarily acts through angotensin II type 1 (AT1) 
receptors on cell membranes. Angiotensin II is a potent pressor substance. 
It is   the primary tropic factor responsible  for the secretion of 
aldosterone by the zona glomerulosa of the adrenal cortex. Angiotensin II 
is also a   potent mitogen .It stimulates vascular smooth muscle cell and 
myocyte growth.  
 
Angiotensin II may play a role in the pathogenesis of 
atherosclerosis apart from its hemodynamic effects. It has a direct cellular 
action on the vessel wall.  
 
      An angiotensin II type 2 (AT2) receptor has been recognized.    It is 
widely distributed in the kidney. It  has the opposite functional effects of 
the AT1 receptor.  
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The AT2 receptor induces vasodilation. It causes sodium excretion. 
It inhibits cell growth and matrix formation. Experimental evidence 
suggests that the AT2 receptor improves vascular remodeling .This effect 
is mainly by stimulating smooth muscle cell apoptosis. This contributes 
to the regulation of glomerular filtration rate. AT1 receptor blockade 
induces an increase in AT2 receptor activity.  
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Fig  1: Renin angiotensin aldosterone system 
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 Renin-dependent hypertension is exemplified by tumours secreting 
rennin. Benign hemangiopericytomas of the kidney, wilms tumours, and 
carcinomas of the kidney are all included. Renin is also produced by 
carcinomas of  pancreas, liver , colon, lung and adrenals. In these cases 
apart from tumour resection therapy of hypertension also includes 
blocking the angiotensin receptors.. 
Renin also acts as a mediator of renovascular hypertension. In this 
scenario  renal artery will be obstructed. This will result in decrease in  
perfusion pressure in the kidney. This leads to secretion of  renin. This 
type of hypertension may become less dependent on renin as time passes 
due to the  secondary damage  to the renal tissue. 
Renin, and angiotensin II are also synthesized locally in many 
tissues, including the brain, pituitary, aorta, arteries, heart, adrenal glands, 
kidneys, adipocytes, leukocytes, ovaries, testes, uterus, spleen, and skin. 
Angiotensin II in tissues may be formed by the enzymatic activity of 
renin or by other proteases, e.g., tonin, chymase, and cathepsins. In 
addition to regulating local blood flow, tissue angiotensin II is a mitogen 
that stimulates growth and contributes to modeling and repair. Excess 
tissue angiotensin II may contribute to atherosclerosis, cardiac 
hypertrophy, and renal failure and consequently may be a target for 
pharmacologic therapy to prevent target organ damage. 
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Angiotensin II is considered  to be the primary tropic factor in 
synthesis as well as secretion of the mineralocorticoid,  aldosterone by  
the adrenal cortex. Aldosterone activates amiloride-sensitive epithelial 
sodium channels which are present in principal cells of collecting ducts of 
the kidney. Thus increases sodium re absorption.   To maintain electrical 
neutrality there will be exchange of potassium and hydrogen ions with 
sodium ions. It may result in hypokalemia and alkalosis.  
The receptors for mineralocorticoid are also present in sweat 
glands, salivary glands and colon. Cortisol is also known to bind these 
receptors. But it is a less potent mineralocorticoid than aldosterone as it 
has to be converted to cortisone. Cortisone does not have affinity for the 
mineralocorticoid receptors.  
Mineralocorticoiod-mediated hypertension is exemplified by 
primary aldosteronism. In this aldosterone synthesis is not under the 
control of  rennin- angiotensin. Renin release is suppressed by increased 
volume. 
It is found that aldosterone also acts on non epithelial targets.  
Activation of mineralocorticoid receptor leads to alteration of structure 
and function of the kidney, heart and  blood vessels. This leads to 
sclerosis of the nephrons, fibrosis of the myocardium and inflammation 
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of vessels due to oxidative stress. High salt intake is found to exacerbate 
these effects.  These effects are amplified by a high salt intake. 
Animal studies show that high aldosterone causes fibrosis of the 
myocardium and hypertrophy of the left ventricle. This myocardial 
fibrosis can be prevented by spironolactone which is an aldosterone 
antagonist. Left ventricular hypertrophy is seen in both essential 
hypertension as well as primary aldosteronism. Spironolactone in low 
doses  reduces the risk of heart failure progression in patients with CHF. 
In the kidney aldosterone excess can lead to glomerular hyperfiltration 
and albuminuria. this effect is reversible with spironolactone and 
adrenelectomy. 
Increased renin-angiotensin-aldosterone activity is not exclusive to 
hypertension. When there is low salt diet or contraction of plasma volume 
rennin-angiotensin activity increases to maintain the homeostasis. In 
cases of congestive heart failure and liver disease there can be secondary 
aldosteronism.  
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Vascular contribution to hypertension 
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Arterial pressure is determined by the compliance of arteries which 
contribute to the peripheral resistance and radius of the artery. Resistance 
offered by the arteries is inversely proportional to the fourth power of the 
arterial radius. So there will be significant increase in resistance with 
minute diminution in size of the lumen. In patients with hypertension 
there is reduction in diameter of the lumen of small arteries and arterioles 
with changes in functional, mechanical or structural aspects of these 
vessels. 
Remodelling means there is alteration in the geometry of the vessel 
wall but there is no change in volume of the vessel. Vascular remodeling 
either hypertrophic or eutrophic  increases the peripheral resistance by 
decreasing the size of the lumen. Low grade inflammation, fibrosis of the 
vessels and apoptosis are also involved in remodeling. Diameter of the 
lumen is also associated with the elasticity of the vessel wall. Vessels 
having  high degree of vessel wall elasticity accommodate large volume 
of  blood with small change in pressure where as vessels which are 
semirigid accommodate small increases in blood volume with greater 
increase in pressure. 
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Arteries are stiff in patients with hypertension.  Vascular structural 
changes cause decreased vascular compliance. This results in elevated 
systolic pressure and widened pulse pressure. Stiffness of the arteries has 
been shown to have definite independent predictive value in causing  
cardiovascular  disease. Usg  and MRI are used for evaluating arterial 
stiffness. 
Abnorrmalities of vascular growth and vascular tone are regulated 
by intracellular pH.   Any alteration in pH changes the ion transport by 
the smooth muscle cells leading to the alterations in the vascular tone and 
contributes to hypertension.  
Three main transport systems are  (1) sodium(Na+)-hydrogen (H)+ 
exchange, (2)Sodium( Na+)-dependent bicarbonate( HCO3–)-chloride(Cl–  ) 
exchange, and (3) cation-independent bicarbonate(HCO3)– chloride(Cl–) 
exchange. Na+-H+ exchanger activity is enhanced  in hypertension. This 
increases vascular tone  .  
Two mechanisms are involved in this process. 1) when sodium 
entry increases it activates  Na+-Ca2+ exchange. This results in increased 
intracellular calcium. 2) Elevated pH enhances calcium sensitivity of the 
vessel wall contractile apparatus  leading to an increase in contractility 
for a given calcium concentration. Increased Na+-H+ exchange increases 
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sensitivity to mitogens  leading to increased growth of vascular smooth 
muscle cells.                        
Vascular tone is also modulated by endothelial function. 
Endothelial cells synthesize and secrete vasoactive substances including 
nitrous oxide. Nitrous oxide palys a major role in vasodilatation. This 
kind of vasodialatation which is endothelium dependant is impaired in 
patients with hypertension. Vascular endothelium produces a substance 
called endothelin.It is a vasoconstrictor peptide. It is shown that 
endothelin antagonists do help in treating resistant hypertension. It is not 
known whether vascular abnormalities of ion transport related to 
hypertension and endothelial dysfunction seen in hypertension are 
primary alterations or secondary consequences of elevated BP. There is 
little evidence that weight loss, aerobic exercise and antihypertensive 
agents help in improving vascular compliance and endothelial function. 
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Pathologic Consequences of Hypertension 
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Hypertension is an independent predisposing factor for heart 
failure, coronary artery disease, stroke, renal disease, and peripheral 
arterial disease (PAD). 
Heart 
Hypertension is considered to be an independent risk factor for  
major health issues.  Heart disease is the most common cause of death in 
hypertensive patients. 
Hypertensive heart disease is the result of structural and functional 
adaptations leading to left ventricular hypertrophy, CHF, abnormalities of 
blood flow due to atherosclerotic coronary artery disease and 
microvascular disease, and cardiac arrhythmia. 
Both genetic as well as hemodynamic factors contribute to left 
ventricular hypertrophy.  
Electrocardiography and Echocardiography  will help in 
diagnosing left ventricular hypertrophy. Echocardiography also measures 
the wall thickness of the left ventricle. Incresed wall thickeness is a risk 
factor for coronary artery disease, stroke, congestive heart failure and 
sudden death. It is shown that strict control of BP can regress or reverse 
this hypertrophy. It is important to reverse or regress this hypertrophy of 
the left ventricle  and  reduce the risk of cardiovascular disease. 
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It is known that congestive heart failure occurs when there is 
systolic dysfunction, diastolic dysfunction or in combined systolic and 
diastolic dysfunction. Diastolic dysfunction ranges from asymptomatic 
cardiac disease to full blown heart failure in patients with hypertension. 
One third of patients with congestive heart failure have diastolic 
dysfunction  and normal systolic function. Hypertensive heart disease 
causes early diastolic dysfunction which is exacerbated by the 
hypertrophied left ventricle and ischemia. 
 
Brain 
Cerebrovascular  disease is considerd as  the second most frequent 
cause of death  worldwide. Hypertension  is the strongest risk factor for 
the development of  stroke. It is estimated that  85%  of strokes are 
ischemic and remainder are haemorragic. Stoke incidence increases 
progressively with increasing blood pressure levels, that too with systolic 
blood pressures in patients older than 65 years. Adequate control of 
hypertension is shown to reduce the incidence of both ischemic as well as 
haemorragic stroke. 
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Hypertension is known to cause impairement in cognition in older 
individuals. Longitudinal studies have shown that there is an association 
between  hypertension during midlife  and cognitive impairment in late 
life. Cognitive decline may be due to single large infarct or due to 
multiple lacunar infarcts. There can be occlusive small vessel disease 
causing ischemis of subcortical white matter leading to cognitive 
dysfunction.  
Cerebral blood flow has autoregultiion. In patients with malignant 
hypertension  there  is impairment of autoregulaton and patients can 
develop encephalopathy. Signs and symtomes are severe headache, 
projectile  vomiting, seizures,  focal neurological deficits,altered mental 
status ,stupor and coma.  
Kidney 
The kidney is considered to be a target as well as source of 
hypertension. Renal disease is the most common cause for secondary 
hypertension. Failure to excrete sodium, increased secretion of renin and 
overactive sympathetic system are all proposed mechanisms in causing 
hypertension. Hypertension is a risk factor for renal injury and end stage 
renal disease. Risk association is more with the systolic than the diastolic 
blood  pressure. Proteinuria is a marker for hypertension induced renal 
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damage. It asseses the severity and predicts the progression of the 
disease. 
Hypertension causes atherosclerosis in preglomerular arterioles.  
This leads to ischemia in glomeruli and post glomerulr structures. There 
is loss of autoregulation of blood flow to the kidney. This results in 
lowering of threshold in causing renal damage.  This  result in a a vicious 
cycle.  
The renal  damage results in nephron loss resulting in  severe 
hypertension, glomerular hyperfiltration, and increased   damage to the 
kidney. This will lead to glomerular sclerosis. The renal tubules 
ultimately become atrophic due to ischemia. Glomerular pathology 
progresses to glomerulosclerosis, and eventually the renal tubules may 
also become ischemic and gradually atrophic. There will be fibrinoid 
necrosis of the afferent arterioles and focal necrosis of tuft of glomerulus 
in malignant hypertension. So it is important to detect renal injury in the 
early stages. 
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Peripheral Arteries 
Though blood vessels contribute to the development of 
hypertension they are also the target organs for the atherosclerotic disease 
resulting from a chronically elevated arterial pressure. As this study is 
about ankle brachial index which is used to detect peripheral artery 
disease, this particular complication is discussed in detail. 
 
PERIPHERAL ARTERY DISEASE 
Arterial occlusive diseases constitute the leading overall cause of 
death in developing as well as developed countries. Adverse life 
threatening  events are due to impaired circulation to major  end organs  
like  heart, brain,  abdominal viscera or extremities. In addition to death 
usually caused by myocardial infarction or stroke, significant disability 
and loss of function are troublesome to the society.  Atherosclerosis  is 
the main pathology behind this arterial occlusive disease. 
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Atherosclerosis 
Atherosclerosis is the main pathology behind major catastrophic 
events like myocardial infarction and stroke. As stated earlier vessels are 
the target organs for increased blood pressure. Alteration in the 
endothelial function, turbulence of blood flow, increased lipids all 
contribute to the development of this pathology. 
 
Fig 2: Atherosclerotic plaque 
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atherosclerosis is a complex, chronic inflammatory process affecting  the 
elastic and muscular arteries. It is both systemic and segmental, with clear 
predilections for certain locations in arteries and relative sparing of 
others. The earliest lesions (fatty streaks) may be detected as early as in 
childhood  in susceptible individuals. An atheromatous plaque will have a  
raised lesion with a soft, yellow, grumouscore of lipid ,mainly cholesterol 
and cholesterol esters, which is covered by a firm, white fibrous cap . 
Besides obstructing blood flow, these plaques weaken the underlying 
media and can rupture by themselves causing acute catastrophic vessel 
thrombosis. 
Before the clinical manifestations develop lesions progress through  
well-characterized pathologic stages. Population-based studies have 
demonstrated important risk factors. The most important independent risk 
factors are hypertension, hypercholesterolemia, smoking, and diabetes 
mellitus. Other risk factors are depicted in the following table. 
 
  
42 
 
Risk Factors for Atherosclerosis 
 
                   Table1: Risk factors for atherosclerosis 
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 Risk factors  
Firmly Established 
Hypertension 
Cigarette smoking 
Hypercholesterolemia 
Diabetes mellitus 
Relative 
Advanced age 
Male gender 
Hyperhomocysteinemia 
Hypertriglyceridemia 
Sedentary lifestyle 
Family history 
 
Table 2: Firmly established and relative risk factors 
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Hypercholesterolemia is associated with increased risk. Of 
prognostic significance is the relative apportioning between the 
subclasses of lipoproteins: the atherogenic, low-density fraction 
(LDL)and the athero protective high-density lipoprotein fraction (HDL). 
Studies have proved a strong positive correlation between cardiovascular 
disease secondary to atherosclerosis and elevated total and LDL 
cholesterol and   strong negative correlation with HDL levels.  
Hypertension is important independent risk factor for coronary 
atherosclerosis. With a continuous increase in relative risk associated 
with each increment of pressure there will be a continuous increase in 
relative risk for coronary atherosclerosis. Hypertension  alone can 
increase the risk of IHD by approximately 60% in comparison with 
normotensive populations.  Left ventricular hypertrophy  probably 
represents a marker of long-standing functional hypertension . 
Cigarette smoking is strongly associated with the incidence of 
atherosclerosis. The mechanism  is likely to  be due to direct toxicity of 
tobacco metabolites on the vascular endothelium, mainly by creating 
oxidant stress. 
Diabetic patients are at markedly increased risk for atherosclerosis, 
leading to higher rates of myocardial events, stroke, and amputation.  
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Age and gender also have an important influence. Prevalence  
increases  with the advancing age.  The increased risk is associated with 
male gender and postmenopausal states in women. 
There are Guidelines for Risk Factor Modification. The following 
table highlights the guidelines. 
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Table 3 
 
 
  
Lipid Management 
Goal: Primary—serum LDL <100 mg/dL; secondary—HDL >35 mg/dL, 
TG <200 mg/dL 
Approach: Diet: <30% fat, <7% saturated fat, <200 mg/day cholesterol; 
specific drug therapy targeted to lipid profile 
Weight Reduction 
Goal:<120% of ideal body weight 
Approach: Physical activity, diet as outlined 
Smoking 
Goal: Complete cessation 
Approach: Behavior modification, counseling, nicotine analogues 
Blood Pressure 
Goal:<140/90 mm Hg 
Approach: Weight control, physical activity, sodium restriction, 
antihypertensive drugs 
Physical Activity 
Goal: At least 30 minutes of moderate exercise 3 to 4 times per week 
Approach: Walking, cycling, jogging, lifestyle and work activities 
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PATHOLOGY AND THEORIES OF ATHEROGENESIS 
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Atherosclerotic plaque is the pathologic hallmark of 
atherosclerosis. Major components of plaque:connective tissue (matrix), 
smooth muscle cells, lipid, and inflammatory cells (predominantly 
macrophages)TT. The presence of lipid within these lesions is a 
prominent  feature. An important concept linking plaque morphology 
with clinical events is the relationship between the fibrous cap and the 
underlying necrotic lipid core.[26] The contents of this central region are 
thrombogenic when exposed to circulating blood,  when a thin fibrous 
cap ruptures or ulcerates. This phenomenon is considered to be an 
important mechanism by which  lesions of relatively mild hemodynamic 
significance may cause acute thrombosis and  tissue infarction.  It is clear 
that both the mechanical characteristics of the plaque and the degree of 
luminal stenosis are of clinical importance. 
The anatomic distribution of atherosclerosis is remarkably 
constant.  It is due to the important role played by the hemodynamic 
stresses.[26] Plaques have tendency to get  concentrated at bifurcations or 
bends, where there are  local alterations in shear stress, turbulence, flow 
separation and stasis are seen. The proximal coronary arteries, infrarenal 
abdominal aorta, iliofemoralarteries, carotid bifurcation, and popliteal 
arteries are commonly affected. Upper extremity vessels, renal, common 
carotid, and mesenteric arteries beyond their origins are usually spared. 
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Atherosclerotic plaques are dynamic lesions . They may undergo 
progression or regression over time. The underlying arterial wall also 
undergoes adaptive remodeling. Arterial enlargement is a well known 
feature of atherosclerosis. It will often result in relative preservation of 
the lumen until plaque volume reaches a threshold size (∼40% stenosis) 
beyond which compensation will fail and lumen narrowing will  become 
progressive[27] . Medial atrophy can also occur, in which  mechanical 
stability of the wall is impaired. This may be one of the mechanism for  
aneurysmal disease.  
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The “response to injury” hypothesis and its  recent modifications 
including  the concept of endothelial cell dysfunction, is the leading 
theory of pathogenesis.[28]  This  hypothesis emphasizes the important 
roles for lipid, inflammation, and thrombosis  in addition to proliferation 
and dysfunction of the cells in the arterial wall. In the earlier versions of 
this theory, a focal denuding injury to the endothelium was thought to be 
triggering event.  
  More recently it is known that endothelial injury includes a 
mechanically intact but phenotypically altered endothelial monolayer . 
The source of  injury may include hemodynamic stress, hypoxia, toxic 
metabolites (e.g., cigarette smoke, homocysteine), or infectious agents 
(cytomegalovirus, Chlamydia, herpesvirus). The final  pathway is a loss 
of the atheroprotective effects of normal endothelium, such as  its barrier 
function, anti proliferative and potent anti adhesive properties. 
The vascular smooth muscle cell (SMC) plays a central role in the 
formation of the lesion. Migration and proliferation of arterial  medial 
SMCs result in a cellular neointima. The intimal SMC undergoes a  
change from a contractile to a secretory state and produces the 
extracellular matrix. Lipid accumulation in the vessel wall is an important 
early event. Oxidation of lipid, particularly LDL particles takes place. It 
produces metabolites which  potentiate the “activated” endothelial 
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phenotype characterized by the expression of procoagulant (e.g., tissue 
factor) molecules, proinflammatory molecules (e.g., leukocyte adhesion 
molecules) and as well as producing a decrease in protective substances 
(e.g., nitric oxide).  
Circulating monocytes are recruited by adhesion to activated 
damaged endothelium or to exposed matrix. They enter the wall to 
become macrophages, and scavenge lipid. T lymphocytes are also 
recruited, and together  all these inflammatory cells secrete  an array of 
cytokines (especially interleukin-1, transforming growth factor-b and 
tumor necrosis factor-a,), causing  the inflammation. Macrophages are 
also  important sources of matrix degrading enzymes involved in wall 
remodeling and plaque stability. 
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Fig 3: Pathogenesis off atherosclerosis  
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Platelets adhere to dysfunctional endothelium, exposed matrix, and 
monocytes-macrophages. The growth factor known as platelet-derived 
growth factor (PDGF) is an important and potent stimulator of both 
migration and proliferation of SMCs, It has been found in abundance in 
atherosclerotic plaques. Apart from platelets different isoforms of PDGF 
are also  produced by endothelial cells and by SMCs.  Locally produced 
growth factors like  basic fibroblast growth factor (bFGF), are likely to 
play a role in the SMC hyperplasia . Amplification occurs by numerous 
potential positive feedback loops between cytokines and growth factors . 
An alternative explanation is given  by the “monoclonal 
hypothesis,” which hinges on the  observation that  many  atherosclerotic 
plaques contain a clonally expanded population of SMCs.[30] The 
developing plaque is considered as a benign SMC neoplasm with an  
alteration in SMC phenotype to the secretory state. But this theory fails to  
explain all  the epidemiologic and pathologic features of atherosclerosis 
and is currently less favored. 
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CLINICAL FEATURES OF PERIPHERAL 
ARTERY DISEASE 
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Asymptomatic 
There is substantial evidence that says that progression of 
underlying peripheral artery disease is same whether it is symptomatic or 
asymptomatic. 
The risk of local deterioration, leading to limb ischemia is not 
related to presence or absence of symptoms of intermittent claudication. 
So it is vital to detect this subgroup of patients early so that protective and 
preventive measures can be applied to reduce adverse outcomes. 
 
Intermittent claudication 
It is pain in calf, thigh and buttocks while walking. The pain is 
described variably as aching, cramping, tightness or fatigue. This is 
relieved by rest. 
Patients with this symptom continues to have functional disability. 
A quarter of these patients will not experience significant deterioration. 
This stabilization of symptoms may be due to the development of 
collaterals or metabolic adaptation by the muscle. 25% of patients with 
intermittent claudication will deteriorate in clinical stage.  This is seen 
most frequently during the first year after the diagnosis (7-9%).  After 
that only 2-3% experience deterioration of symptoms.  This apparent 
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difference is because patients subjective perception of severity of 
claudication. When these patients are subjected to comprehensive 
functional status assessment their measured walking distance does  
decrease over the course of time. Only 1-3.3% of patients with 
intermittent claudication will require amputation over a 5 year     
period(31, 32).  
A changing ABI predicts that patients disease is deteriorating. 
Studies have shown that patients with intermittent claudication who are in 
lowest strata of ankle brachial index have 8.5% risk of progression to 
severe ischemia or actual limb loss(33). 
 
Critical limb ischemia 
It refers to ischemic pain in the foot during rest with or without 
ulcers or gangrene. The estimated incidence ranges between 500-1000 
new cases per million population per year. It is also a marker for 
generalized severe atherosclerosis. So these patients have poor prognosis 
.The primary goal of treating these patients is to relieve severe ischemic 
pain, prevent loss of the extremity, heal the ulcers, improve patients’ 
quality of life and prolong survival. 
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Local physical examination findings 
Peripheral arterial disease patients will have change in colour of 
the limb, change in temperature of the skin , decreased hair growth, 
atrophy of the muscles and hypertrophy of nails. Bruit may be heard over 
carotid artery, femoral artery or aorta . Absence of bruit does not rule out 
the presence of arterial disease. Ankle Brachial index, segmental pressure 
technique, Doppler study, transcutaneous oximetry, and arteriography are 
all used in diagnosing peripheral artery disease. 
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ANKLE BRACHIAL INDEX 
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Ankle Brachial Index:   
The ankle brachial index a ratio. It has systolic pressure at the 
ankle as numerator and systolic pressure  in the arm as denominator. The 
measurement is fast and quantification is easy. It is used to diagnose and 
evaluate peripheral artery disease. 
Recently ABI is used to evaluate patients who are at increased risk 
for cardiovascular disease. An ABI < =0.9 has been shown to increase the 
risk of future  myocardial infarction.  This risk is related to the degree of 
reduction in ABI and it is independent of other known risk factors for 
cardiovascular disease. 
 ABI provides additional risk stratification in individuals with 
Framingham risk between 10-20% in 10 years.  In this intermediate risk 
group abnormal ABI will move the patient to high risk group requiring 
secondary prevention strategy where as  normal ABI  will lower the risk 
requiring primary prevention strategy. It also indicates that peripheral 
vessels are having atherosclerosis even though patients are asymptomatic. 
In patients who have no symptoms reduced ABI is associated with 
reduction in functional capacity  of limbs. This reduction in limb function 
is defined as decreased speed of walking and/or reduced walking distance 
observed during a six minute walk test.  
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Primary care medicine should include ABI measurement as a 
routine. In this context screening of individuals aged 50-69 years  who 
are diabetics and hypertensives or screening all patients above seventy 
years showed prevalence of PAD  as 29% in one study. ABI  reporting 
requires a change of 0.15 in an isolated measurement or >0.10 if 
associated with change in patients’ present clinical status , because in 
literature the reproducibility of ABI varies. The cut off point for 
diagnosing PAD is <=0.9  at rest(34). 
 
Advantages of  detecting reduced ABI: 
a. Helps in confirming the diagnosis of PAD  
b. Helps in detecting significant PAD in asymptomatic individuals 
c. Helps in identifying patients with reduced limb function  
d. As a prognostic indicator of cardiovascular disease. 
e. Helps in risk stratification , with the lower spectrum having poor 
prognosis. 
 
The normal ABI is >1.The cut off to diagnose PAD is <=0.9.  
Individuals with claudication are known to have ABI in the range of 0.5-
0.7. Those who have rest pain are in 0.3-0.5 range. Patients with gangrene 
have ABI of less than 0.3. These ranges vary according to the degree of 
vessel all compressibility. The test is less reliable in people with heavily 
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calcified arteries. Due to non compressibility in diabetes and ESRD some 
patients may have ABI =1.4. These individuals need additional diagnostic 
tools for the assessment of the disease 
 ABI grading of peripheral   artery disease 
 
Table : 4 ABI grading of peripheral artery disease 
 
Experts believe that asymptomatic patients with low ABI should be 
treated similar to symptomatic patients as cardiovascular risk remains the 
same. A prospective study by name get ABI (German Epidemiological 
Trial on Ankle Brachial Index) showed that low ABI was associated with 
increased CVD risk and there is no statistically significant difference 
between asymptomatic and symptomatic groups.  
 
ABI Disease grading Disease severity 
>1.3 0 Non compressible 
0.95-1.30 0 Normal 
0.60-0.94 1 Minimal 
0.50-0.59 2 Mild  
0.26-0.49 3 Mild to moderate 
0.20-0.25 4 Moderate 
0-0.19 5 Severe 
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Hence it is important to detect these patients with low ABI even 
when they are asymptomatic so that preventive measures can be 
applied to reduce the CVD risk. These include lifestyle modification, 
antiplatelet therapy, statins or ACE inhibitors. 
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AIM OF THE STUDY 
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 Aim of the study is to study the effect of hypertension on ankle 
brachial index. 
 
 To assess the effect of following  factors  on ankle brachial index 
 
 
 Age 
 Sex  
 Body Mass Index 
 Duration of  Hypertension 
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MATERIALS AND METHODS 
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SELECTION OF SUBJECTS: 
 
Hypertensive patients who visit the Department of Medicine were 
enrolled  for the study after excluding exclusion criteria.   
 
Inclusion criteria : 
 Hypertensives  according to jnc7. 
 
 
Exclusion criteria : 
 Patients who  have diabetes mellitus 
 Patients who have chronic kidney disease 
 Patients who have coronary artery disease 
 Patients who have dyslipidemia 
 Patients who are smokers 
 Patients with symptoms of peripheral artery disease 
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Setting  :   Kilpauk Medical College 
Study design : Cross sectional study 
Duration of study :  6 months  
Sample size  :  198 
The data of each patient will be collected on a proforma specially 
designed for this study. This proforma includes  
name,  
age,  
height of the patient,  
weight of the patient,  
systolic blood pressure of the patient 
diastolic blood pressure of the patient 
duration of hypertension    
ankle brachial index. 
This data  will be analysed for statistical significance and 
correlation. 
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PROFORMA 
NAME  :                                                                                                  
I.P/O.P.NO.  : 
AGE/SEX  :                                                                                              
DATE  :                  
OCCUPATION :                                                                                 
ADDRESS  :                       
 
 
CONTACT NO : 
COMPLAINTS : 
HISTORY  : 
H/O HYPERTENSION DURATION  : 
 
SIGNIFICANT PAST HISTORY : 
  
FAMILY HISTORY   : 
PERSONAL HISTORY   : 
TREATMENT HISTROY(DRUGS) : 
GENERAL PHYSICAL EXAMINATION : 
 
HT:    WT:     BMI: 
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VITALS: 
BP:   PR:   RR: 
 
 
SYSTEMIC EXAMINATION: 
CVS: 
RS: 
P/A: 
CNS: 
Others  
 
INVESTIGATIONS:  
Ankle brachial index 
RFT  
 
 
 
ECG  
ECHO 
Lipid profile 
Triglycerides Total Cholesterol HDL- C LDL-C VLDL-C 
     
 
  
Random blood 
sugar Urea Creatininie 
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ANKLE BRACHIAL INDEX MEASUREMENT 
 
Blood pressure was measured in both ankles and arms with the 
patient in supine position. Systolic blood Pressure was measured in both 
arms with the help of Blood pressure cuff and Doppler instrument (Ultra 
Tec PD1 v with a vascular probe of 5 MHz ) in the ante cubital fossa. 
Systolic pressure was measured at the left and right dorsalispedis arteries. 
If it was not found in dorsalis pedis arteries, systolic blood pressure was 
recorded at the left and right posterior tibial arteries. The blood pressure 
cuff was applied  to the ankle just proximal to the medial malleoli.  
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Fig 4 : ABI measurement 
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Blood pressure measurement   
Blood pressure of the patient was measured with the help of 
mercury sphygmomanometer. It was measured after making patient 
relaxed for at least five minutes with the blood pressure cuff applied on 
the arm. It was measured in sitting position in both upper limbs, with the 
apparatus at the level of heart. The mean of the two readings taken at 
intervals of at least two minutes was used for data analysis. Pulse 
pressure was calculated by the formula: pulse pressure = systolic blood 
pressure - diastolic blood pressure. 
 
Fig 5: Blood pressure measurement 
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Body Mass Index (BMI) measurement: 
Body Mass Index was calculated with the help of the following 
formula  
                                                                   Weight in Kg 
Body mass index                    =                    
                                                                   Height in m2      
 
 Patients’ weight was measured and it was expresses in kilogram. 
 Patients’ height was measured and it was expressed in meters. 
Body mass index was calculated using the above formula.  
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Fig 6:  Weight and Height measurement 
 
WHO classification of BMI : 
Normal    : 18.5-24.9kgs 
Overweight    :  25-29.9kgs 
Obese    :  >30kgs 
. 
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STATISTICAL  ANALYSIS : 
          Data obtained were maintained in the master chart in Microsoft 
Excel format and analysis was done using SPSS 11.5 version. Data was 
arranged in proportions. The variables were compared using pearson 
correlation coefficient. A p value of <0.05 was considered to be 
statistically significant. 
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OBSERVATIONAL ANALYSIS 
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Age distribution in this study 
 
       
 
 
 
 
 
 
 
 
 
Tables 5: Age distribution among the subjects 
 
  
Age in years Number of subjects 
21-30 7 
31-40 29 
41-50 68 
51-60 67 
61-70 23 
71-80 2 
81-90 2 
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34%
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Distribution of Age  
 
 
 
Fig 7: Distribution of age 
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A total of 198 patients were included in this study 
 3 % were in the age group of 21- 30 years;  
 15% were in the age group 31-40 years;34% were in the age group 
of 41-50 years;  
 34% were in the age group of  51-60 years;12% were in the age 
group of 61-70 years;  
 1% were in the age group of 71-80 years;  
 1 % were in the age group 81- 90 years.  
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31%
69%
DISTRIBUTION OF SEX
MALE FEMALE
Distribution of sex in this study 
Male 62 
Female 136 
 
Table 6: Distribution of sex 
 
 
Fig 8: Distribution of sex 
 Out of 198 patients studied 136 were females(69%) and 32 
were males(32%). 
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 Distribution of  BMI 
 
 
 
 
 
 
 
 
Table7 : Distribution of subjects according to BMI 
 
  This table depicts the BMI distribution in this study.  This is 
plotted into a pie diagram for further simplification. 
 
  
NORMAL                  104 
OVERWEIGHT            89 
OBESE                             5 
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Fig 9: Distribution of BMI 
 
In my study there were 53% patients with normal BMI. There were 
45% of patients were overweight and 2% were obese 
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35%
26%
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Distribution according to the duration of  hypertension 
     
      
Fig 10: Distribution of  Hypertension duration 
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Out of 198 patients,  
 42 patients (21%) were having hypertension  for past 1-5 years; 
 69 patients (35%) were having hypertension for  6-10 years; 
 52 patients (26%) were having  hypertension for 11-15 years; 
 22 patients (11%) were having hypertension  for  16-20 years; 
 9 patients (5%) were having hypertension for 21-25 years  
 4 patients (2%)  were having hypertension for 26-30  years. 
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 Fig 11:Correlation between age and ABI  
 
 The above scattered diagram shows the relation of ABI with the 
age of subjects. The correlation trendline indicates that there is decline of 
ABI with increase in age and this change was found to be statistically 
significant with p value of 0.003. 
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Comparison between age and ABI 
 
Age <=0.9 >0.9
21 - 30 0 100
31 - 40 27.6 72.4
41 - 50 50 50
51 - 60 50.7 49.3
61 - 70 60.9 39.1
71 - 80 100 0
81 - 90 100 0  
Table 8: Comparison between age and sex of study subjects 
 
Patients were sorted according to their age as shown in the above 
table. Percentage of patients with ABI <= 0.9 and those with >0.9 are 
determined in each group and plotted in the form of bar diagram. 
 
  
87 
 
0
20
40
60
80
100
21 - 30 31 - 40 41 - 50 51 - 60 61 - 70 71 - 80 81 - 90
0
27.6
50 50.7
60.9
100 100100
72.4
50 49.3
39.1
0 0
%
AGE
COMPARISON BETWEEN AGE AND ABI
≤ 0.9 > 0.9
Comparison between Age and ABI 
 
 
 
Fig 12: Showing comparison between age and ABI 
 
Above diagram indicates that the percentage of patients with ABI 
<=0.9 increases as age increases. 
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Fig 13: Correlation between BMI and ABI 
  
 This diagram shows us the correlation of ABI with BMI. The 
correlation trendline indicates that  the ABI decreases with increase in 
BMI. This change is found to be statistically significant with p value of 
0.0001. 
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Fig 14 Bar diagram showing comparison between BMI and ABI 
 
The above figure shows that percentage of patients with ABI ≤ 0.9 
increases as BMI increases. 
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Fig 15:Correlation between hypertension duration and ABI 
This scattered diagram shows the correlation between the duration 
of hypertension with ABI. The correlation trendline indicates that ABI 
decreases as duration of hypertension increases. This was found to be 
statistically significant with p value of  0.0001. 
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Comparison between hypertension duration and ABI 
 
Duration ≤0.9 >0.9
1 - 5 YEARS 11.9 88.1
6 - 10 YEARS 23.2 76.8
11 - 15 YEARS 80.8 19.2
16 - 20 YEARS 86.4 13.6
21 - 25 YEARS 88.9 11.1
26 - 30 YEARS 100 0
 
 
Table 9: Comparison between hypertension duration and ABI 
 
Percentage of patients with ABI ≤ 0.9 were calculated for various 
duration of hypertension as shown in the table. This is depicted in the bar 
diagram. 
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Fig 16: Comparison between hypertension duration and ABI 
 
This diagram shows that percentage of patients with ABI≤ 0.9 
increases as duration of hypertension increases. 
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Fig 17: Correlation between systolic blood pressure and ABI 
  
The above diagram shows that our patients fall between SBP of 
146 to 190 mm Hg. It also depicts that as SBP increases ABI decreases 
which is statistically significant with p value of 0.0001 
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Fig 18 :Correlation between diastolic blood pressure and ABI 
 
The above scattered diagram shows as DBP increases ABI 
decreases and this was found to be statistically significant with the p 
value of 0.039. 
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Fig 19 : Correlation between pulse pressure and ABI 
 
This scattered diagram shows correlation between pulse pressure 
and ABI. The correlation gtrendline indicates that as pulse pressure 
increases ABI decreases. This was found to be statistically significant 
with the p value of 0.0001. 
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Fig 20: Comparison between sex and ABI 
 
In this study 46.8% of males have ABI ≤ 0.9 and 47.8% of females 
have ABI≤ 0.9. 
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There were a total of 198 patients enrolled in this study.    
 
 Prevalence of asymptomatic PAD was found to be 47% 
 ABI was ≤ 0.9 in 46.8% males 
 ABI was ≤ 0.9 in 47.8% females 
 There was inverse correlation between age and ABI 
 There was inverse correlation between ABI and BMI 
 There was inverse Correlation between ABI and systolic pressure 
 There was inverse correlation between ABI and diastolic pressure 
 There was inverse correlation between ABI and pulse pressure 
 There was inverse correlation between ABI and duration of 
hypertension.  
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CONCLUSION 
 
             Subclinical peripheral artery disease is common in hypertensive 
patients even though they do not have other co morbidities. Measuring 
the Ankle Brachial Index is an efficient method to detect patients who are 
at increased cardiovascular risk. It would help treating physician to 
advocate preventive measures to reduce the risk. 
It would be beneficial to include Ankle Brachal index as a routine 
in primary care set up as it is safe, easy and patient friendly. Measuring  
ABI may significantly reduce the future cardiovascular events in 
hypertensive patients . 
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Abbreviations  
ABI  - Ankle Brachial Index 
PAD – Peripheral Artery Disease. 
CAD – Coronary Artery Disease. 
CVD  - Cardio Vascular Disease 
IHD - Ischemic Heart Disease 
ESRD – End Stage Renal Disease 
BP – Blood Pressure 
SBP – Systolic Blood Pressure 
DBP – Diastolic Blood Pressure 
PP – Pulse Pressure 
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MASTER CHART 
serial 
no. name age sex 
op 
no. BMI 
HTN 
duration SBP DBP PP ABI 
1 Maya 40 F 2089 29.51 6 154 70 84 0.87 
2 Kumar 56 M 2094 28.12 14 170 98 72 0.89 
3 Amul raj 40 M 2073 27.6 6 174 102 74 0.93 
4 Rukmani 58 F 2093 26.47 17 150 100 72 0.93 
5 Astharalli 54 M 2091 30.75 14 184 120 64 0.85 
6 Saraswathi 53 F 2095 20.77 6 146 100 46 0.95 
7 Sundaram  60 M 2090 24.97 20 168 110 58 0.89 
8 Jesi 60 F 2070 20.88 22 168 92 76 0.84 
9 Ibrahim 44 M  2035 26.95 12 170 100 70 0.89 
10 Divasigmani 73 F 2069 24.03 30 160 82 78 0.88 
11 Kamatchi 51 F 2071 26.48 15 150 96 54 0.89 
12 Prabha 36 F 2068 20.08 5 152 98 42 1.02 
13 Lalitha 35 F 2072 23.61 5 148 110 38 1.01 
14 Shanmuga sundaram 52 M 2067 28.37 12 180 114 66 0.85 
15 Jothika  64 F 2088 30.8 28 180 98 82 0.83 
16 K. kantha 45 F 2080 22.82 7 148 104 44 0.94 
17 Abeya 68 F 2086 21.36 24 150 100 46 1.05 
18 Janaki 48 F 2078 23.83 16 150 100 50 1 
19 Sagunam 51 F 2084 20.77 10 146 100 54 1.02 
20 Yousuf 55 M 2077 30.46 12 168 110 58 0.89 
21 Padma 70 F 2083 21.99 28 174 96 78 0.87 
22 Theresa 49 F 2076 27.26 10 180 98 82 0.83 
23 Vasantha 36 F 2082 24.34 5 146 100 46 1.04 
24 Vanaja 60 F 2075 28.84 20 170 90 80 0.77 
25 Radha krishna 43 M 2081 25.8 8 166 94 72 0.84 
26 Devaki 57 F 2087 23.8 16 150 96 56 1.02 
27 Devdas 61 M 2074 23.6 8 158 90 58 1.02 
28 Tamilselvi 44 F 2033 20.6 8 152 96 56 0.97 
29 Shanmugam 54 M 2066 21.6 12 154 90 58 1.03 
30 Kasthuri 55 F 2034 22.4 10 154 100 54 0.96 
31 Nagarani 60 F 2045 30.8 22 170 90 80 0.76 
32 Albert 57 M 2037 25.8 16 174 88 86 0.87 
33 Renuka Devi  49 F 1952 24.9 12 160 118 42 0.81 
34 Mohankumar 53 M 2038 23.4 8 160 90 48 1.02 
35 Sangeetha 56 F 1886 24.8 11 146 98 48 1.04 
36 Ranjitha 60 F  2039 27.9 18 168 84 84 0.83 
37 Harilal 43 M 1887 22.1 3 148 110 38 1.01 
38 Babu  52 M 2040 26.4 6 164 90 74 0.91 
39 Pushpa 68 F 1889 27.3 18 180 100 80 0.77 
40 Senthil raman  50 M 2044 27.8 12 168 100 68 1 
41 Malliga 52 F 1875 24.1 14 150 100 44 1.01 
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42 Jayalakshmi 52 F 1880 23.8 9 156 110 78 0.94 
43 Violet Mary  70 F 2041 26.2 30 160 110 50 0.8 
44 Marhamma 50 F 1890 25.9 8 160 94 66 0.93 
45 Sarasu 55 F 1884 24.3 9 148 96 76 1.02 
46 Narasamma 38 F 2042 21.6 6 152 104 48 0.92 
47 Ganesh moorthy 55 M 1951 27 12 174 102 72 0.87 
48 vanalakshmi 54 F 1918 25.7 12 162 108 54 0.79 
49 Mumtaj 61 F 1954 24.8 14 152 98 52 1.01 
50 Rani 35 F 1915 24.1 4 156 112 50 1.01 
51 Muthammal 57 F 1958 22.6 9 154 96 48 1.02 
52 Andal 65 F 1894 26.1 16 172 108 64 0.82 
53 Ranjini 54 F 2041 27.9 13 152 102 50 0.84 
54 Mark 68 M 1960 25.6 18 168 104 64 0.89 
55 Karthikeyan 45 M 2043 26.4 11 172 118 54 0.82 
56 Jagadhammal 64 F 1873 23.3 12 162 98 60 0.92 
57 Ramalakshmi 62 F 1920 22 6 170 90 80 0.82 
58 Egavalli 42 F 1876 24.9 7 152 110 56 0.97 
59 Chinnamma 55 F 1871 24.6 8 148 104 46 0.94 
60 Kannan 51 M 1881 23.5 7 158 80 44 0.94 
61 Prashanth 46 M 1882 22.6 6 152 90 62 1.1 
62 Prema 37 F 1828 22.3 3 152 92 78 1.01 
63 Anjalamma 36 F 1830 23.3 4 148 100 68 1.02 
64 Rani 60 F 1824 27.6 22 182 106 76 0.83 
65 Geetha 56 F 1825 26.7 16 172 114 58 0.87 
66 Amaravathi 48 F 1827 25.8 12 174 120 54 0.86 
67 Vaniyamma 49 F 1813 20 9 148 102 54 1.01 
68 Devanesan 50 M 1816 19.7 5 156 80 72 1.02 
69 Meenakshi 55 F 1819 24.4 7 146 98 70 1.02 
70 Saroja 50 F 1787 24.8 8 146 104 46 1.02 
71 Maliga 42 F 1789 26.6 11 178 90 88 0.85 
72 Subalatha 20 F 1791 21.9 1 154 104 60 1.01 
73 Sudha 32 F 1793 23.8 2 152 98 64 1.03 
74 Elizabeth 49 F 1774 24 9 152 106 50 1.05 
75 Elumalai 26 M 1776 22.2 1 152 88 78 1.06 
76 Bharathi 48 F 1779 25.4 15 174 116 58 0.87 
77 Meera 58 F 1782 24.7 8 152 96 72 0.97 
78 Sakunthala 70 F 1785 20.3 9 156 110 46 0.94 
79 Baby 58 F 1770 23.1 7 154 98 38 1.02 
80 Sundar  45 M 1772 27.9 13 178 96 82 0.78 
81 Mahalakshmi 35 F 1752 27.9 5 168 102 66 0.84 
82 Murugesan 52 M 1755 25.8 8 158 104 54 0.96 
83 Masilamani 50 M 1758 23.3 6 154 98 54 1.03 
84 Sambulingam 82 M 1761 23.3 24 182 112 70 0.87 
85 Kalyani 40 F 1763 22.7 6 160 100 66 0.98 
86 Deepalakshmi 34 F 1694 24.8 2 158 92 66 0.98 
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87 Sumathi 38 F 1568 23.8 4 148 110 54 1.02 
88 Nagalakshmi 42 F 1499 25.5 11 178 112 66 0.87 
89 Valli 55 F 1765 28.5 15 184 112 72 0.82 
90 Subramani 60 M 1798 25 22 180 98 82 0.84 
91 Manaravi 39 M 1750 21.2 4 154 102 46 1.01 
92 Arthi 32 F 1737 23.6 3 156 106 50 0.94 
93 Subburayan 60 M 1748 22.6 6 152 88 62 1.05 
94 Devi 36 F 1735 21.2 5 156 104 50 1.01 
95 Mumtaj begam 45 F 1742 28.5 11 164 98 66 0.86 
96 Ramani 45 F 1739 24.5 8 154 110 44 0.94 
97 Varadhamma 66 F 1745 22.3 20 168 86 82 0.85 
98 Elumalai samy 60 M 1943 26.2 22 178 112 66 0.87 
99 Chellammal 62 F 1741 27.4 18 172 90 82 0.8 
100 Karpagam 52 F 1717 23.3 8 160 98 50 0.93 
101 Esther 50 F 1746 29.6 14 184 106 78 0.81 
102 Jamuna 40 F 1722 24.2 6 152 96 56 1.02 
103 Parimala 60 F 1708 30.7 22 182 100 82 0.85 
104  Bharathiyammal 56 F 1710 21.3 8 158 104 52 1.01 
105 Dhanaraj 40 M 1720 25.3 9 168 92 76 0.88 
106 Rahimbee 40 F 1716 23.8 6 158 110 52 1.02 
107 Krishnaveni 50 F 1688 22.4 7 152 98 54 1.05 
108 Immali 59 M 1715 25.2 20 178 88 90 0.85 
109 Lakshmi 46 F 1693 25.3 12 172 114 58 0.89 
110 Mariya 50 F 1671 26.8 14 178 120 58 0.87 
111 Mary 46 F 1673 24.3 8 158 110 58 1.02 
112 Annamalai 71 M 1676 22.9 16 184 116 68 0.89 
113 Nagamma 39 F 1670 27.4 6 188 102 86 0.86 
114 Ettiyappan 30 M 1677 21.3 4 152 96 56 1.01 
115 Jalandhara 51 F 1663 24.4 8 158 102 60 0.98 
116 Govindhammal 65 F 1664 25.4 16 178 88 86 0.89 
117 Vijayakumar 30 M 1668 23.8 2 164 112 48 1.02 
118 Irudhayam 45 M 1650 23.3 8 156 98 48 1.02 
119 Radha   42 F 1669 27.7 9 172 106 66 0.87 
120 Renuka Devi  53 F 1651 24.2 12 162 102 56 0.98 
121 Ayyanar 51 M 1653 22.9 8 152 90 62 1.05 
122 Nagarajan 66 M 1660 25.6 18 180 94 86 0.84 
123 Jayaraman 57 M 1632 22.9 11 168 98 70 0.89 
124 Thilagavathi 48 F 1633 24.4 8 164 98 60 0.98 
125 Mani 45 M 1636 23.3 9 160 100 60 0.98 
126 Gowri 55 F 1638 25.9 14 178 110 68 0.89 
127 Rosy 43 F 1639 24.8 8 158 88 66 0.98 
128 Gibisha 45 F 1644 25.1 11 182 110 72 0.89 
129 Boopathy 54 M 1612 24 12 158 80 54 1.01 
130 Rooja 44 F 1645 27.3 14 184 104 80 0.86 
131 Rajammal 65 F 1615 24.6 12 162 90 52 0.97 
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132 Vadivel 41 M 1646 25.3 9 182 98 84 0.89 
133 Padhamma 35 F 1617 29.5 5 178 120 58 0.89 
134 Chandra 42 F 1620 23.9 10 168 90 78 0.88 
135 Shanthi 28 F 1599 22.3 1 164 90 84 0.93 
136 Pencillamma 70 F 1600 19.5 10 148 100 48 1.02 
137 Raghu 42 M 1602 21.1 6 154 92 52 1.02 
138 Sakunthalammal 48 F 1587 26.6 10 178 102 76 0.88 
139 Selvi 45 F 1591 26.5 10 176 90 86 0.86 
140 Valliyammal 41 F 1595 22.1 4 156 90 70 0.98 
141 Sajin 31 M 1588 24.8 2 156 100 56 0.97 
142 Munniyammal 59 F 1540 29.8 14 178 100 78 0.86 
143 Vevekannadha 35 M 1528 26.1 5 172 96 76 0.88 
144 Raju 44 M 1543 27.5 11 180 96 84 0.85 
145 Jyothilakshmi 30 F 1532 24.8 2 160 98 62 0.95 
146 Sarojini 56 F 1530 26.6 16 180 94 86 0.85 
147 Raja subramani 57 M 1536 26.1 12 170 92 86 0.85 
148 Mythili 38 F 1401 28.1 6 154 96 58 0.96 
149 Jaya 59 F 1435 26.4 14 164 88 76 0.86 
150 Violet  55 F 1418 22.1 5 158 86 62 1.02 
151 Ranjana 49 F 1510 23.3 5 162 88 66 0.97 
152 Anjamma 45 F 1511 23.6 3 158 80 62 1.06 
153  Mary joseph 49 F 1485 21.6 6 162 100 62 0.97 
154 Kasthuriyammal 40 F 1512 26.1 5 172 88 84 0.88 
155 Kumar babu 42 M 1489 23.8 8 180 104 76 0.88 
156 Alamelu 48 F 1513 24.1 8 154 92 62 1.01 
157 Neelaveni 38 F 1498 23.1 6 160 90 70 0.98 
158 Shiva 52 M 1514 20.5 4 160 100 64 0.92 
159 Kalavathi 54 F 1521 24.3 10 154 104 64 1.05 
160 Saroja 48 F 1469 27.7 10 186 120 66 0.87 
161 Kasthuri rani 50 F 1452 27.1 5 172 100 72 1.93 
162 Pooniyammal 46 F 1471 27.9 12 182 110 72 0.87 
163 Mary karvallo 42 F 1464 25.9 11 182 110 72 0.89 
164 Satidevi 41 F 1478 26.7 10 172 110 62 0.89 
165 Karpaga veni 55 F 1447 27.3 5 152 94 74 0.97 
166 Fathima 60 F 1450 27.8 15 182 102 80 0.85 
167 Pappa 53 F 1453 28.6 12 172 96 76 0.86 
168 Gunasheeli 41 F 1460 27.4 9 174 98 76 0.85 
169  Poongodi 46 F 1446 27.1 12 172 98 74 0.88 
170 Shamila 30 F 1430 26.7 1 174 90 68 0.93 
171 Ramabai 48 F 1445 29.5 16 168 110 58 0.89 
172 Nirmala 44 F 1436 25.1 4 162 110 42 0.97 
173 Devika 50 F 1427 28.7 12 178 110 68 0.87 
174 Baskaran 65 M 1423 23.2 5 152 90 50 1.05 
175 Sakunthaladevi 50 F 1433 26.1 12 176 100 76 0.88 
176 Natarajan 45 M 1428 27.8 8 178 120 58 0.89 
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177 Malini 42 F 1432 25.1 4 164 98 72 0.96 
178 John 48 M 1425 23.6 8 154 96 56 1.03 
179 Rathinammal 42 F 1441 25.2 4 162 90 64 0.96 
180 Mary jawahar 85 F 1437 25.1 20 158 110 48 0.89 
181 Rajeshwari 52 F 1421 26.2 11 168 102 66 0.89 
182 Samanthi 39 F 1403 26.2 5 182 120 62 0.89 
183 Amudha 40 F 1406 22.8 6 154 80 74 1.05 
184 Ellappa 67 M 1381 22.9 15 166 80 86 0.89 
185 Paul raj 52 M 1384 24.1 20 172 110 62 0.89 
186 Arjunan 55 M 1388 24.4 5 156 90 58 0.97 
187 Sekar 48 M 1354 23.3 6 154 90 66 0.96 
188 Durai 47 M 1359 25.6 12 168 88 80 0.89 
189 Rajan 50 M 1363 24.4 8 160 90 70 0.95 
190 Ranganathan 62 M 1399 20.7 12 158 90 62 0.93 
191 Pasupathi 47 M 1416 22.1 5 154 100 54 1.01 
192 Kala  53 F 1521 29 14 190 122 68 0.88 
193 Johnson 51 M 1497 23.5 4 152 90 64 1.06 
194 Allis 70 F 1407 25.1 20 172 100 72 0.87 
195 Annammal 65 F 1397 26.5 22 176 92 84 0.85 
196 Shivaraj 52 M 1517 25.5 5 168 88 80 1 
197 Jeyakumari 59 F 1414 29.6 15 174 120 54 0.87 
198 Panchali 56 F 1455 25.7 12 176 116 60 0.89 
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